High risk pulmonary embolism in oncology Review article
Article Sidebar
Main Article Content
Abstract
Pulmonary embolism is a frequent complication of both cancer and the oncologic therapy. There is still discussed the subject of optimal antithrombotic prophylaxis in oncology. This article presents the patient with metastatic prostate cancer who experienced complications during therapy with lenalidomide and docetaxel. The doctors from emergency department diagnosed in this patient neutropenic fever with suspicion of pneumonia and pleuritis. Meanwhile the diagnostic scheme proceeded in the Department of Oncology according to the guidelines of European Society of Cardiology helped to diagnose high risk pulmonary embolism. The article presents a case report of effective multi-disciplinary diagnosis and treatment of oncological patients with complications after chemotherapy. The discussion includes current obligatory recommendations of the American and European scientific societies for primary and secondary antithrombotic prevention in patients with cancer.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., Kakkar A., Kuderer N.M., Levine M.N., Liebman H., Mendelson D., Raskob G., Somerfield M.R., Thodiyil P., Trent D., Francis C.W.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 2007 Dec 1; 25(34): 5490-505.
3. Khorana A.A., Streiff M.B., Farge D., Mandala M., Debourdeau P., Cajfinger F., Marty M., Falanga A., Lyman G.H.: Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J. Clin. Oncol. 2009 Oct 10; 27(29): 4919-26. Epub 2009 Aug 31.
4. Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej: „Konsensus Polski” — aktualizacja styczeń 2009. Acta Angiologica 2009; 15(2).
5. Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej: „Konsensus Polski” — aktualizacja 2011. Acta Angiologica 2011; 17(Supl. A).
6. Krzanowski M., Spławiński J.: Czy można stosować antywitaminy K w prewencji żylnej choroby zakrzepowo zatorowej? – na marginesie zaleceń Profilaktyka i leczenie żylnej choroby zakrzepowo-zatorowej. Acta Angiol. 2009; 15(2): 96-100.
7. Khorana A.A., Francis C.W., Culakova E. et al.: Risk factors for chemotherapy-induced venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2829.
8. Stanisławiak J., Markowska J.: Powikłania zakrzepowe w onkologii. Przegląd Menopauzalny 2010; 4: 203-206.
9. Blom J.W., Vanderschoot J.P., Oostindiër M.J. et al.: Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. 2006; 4: 529-35.
10. Heit J.A., Silverstein M.D., Mohr D.N. et al.: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 2000; 160: 809-15.
11. Cavo M., Zamagni E., Tosi P. et al.: First-line therapy with thalidomide and dexamethazone in preparation for autologous stem cell transplantation in multiple myeloma. Haematologica 2004; 89: 826-31.
12. Rajkumar S.V., Blood E., Vesole D. et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2006; 24: 431-6.
13. Wagman L.D., Baird M.F., Bennett C.L. et al.: Venous thromboembolic disease: Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2006; 4: 838-869.
14. Mandala M., Falanga A., Roila F.: Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann. Oncol. 2008; 19(suppl 2): ii126-127.
15. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., Ray J.G.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126(Suppl 3): 338S-400S.
16. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., Colwell C.W.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133(Suppl 6): 381S-45.
17. Opolski G., Krzakowski M., Szmit S., Banach J., Chudzik M., Cygankiewicz I., Drożdż J., Filipiak K.J., Grabowski M., Kaczmarek K., Kochman J., Lewek J., Maciejewski M., Miśkiewicz Z., Niwińska A., Pieńkowski T., Piestrzeniewicz K., Sinkiewicz W., Wranicz J.K., Zawilska K.: Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologic proceeding with patients with breast cancer. Kardiol. Pol. 2011; 69(5): 520-530.